Log In
Print
BCIQ
Print
Print this Print this
 

tregalizumab (BT-061)

  Manage Alerts
Collapse Summary General Information
Company Biotest AG
DescriptionHumanized mAb against CD4
Molecular Target CD4
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$480.0M

$85.0M

$395.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today